Percent free prostate-specific antigen does not improve the effectiveness of prostate cancer detection in Chinese men with a prostate-specific antigen of 2.5–20.0 ng/ml: a multicenter study

被引:0
作者
Maping Huang
Yurong Lin
Abai Xu
Matthew Uhlman
Xiangrong Deng
Xuanting Lin
Sifeng Wu
Pengfei Diao
Keji Xie
Ping Tang
机构
[1] Guangzhou Medical University,Department of Urology, Guangzhou First People’s Hospital
[2] Guangdong Provincial Work Injury Rehabilitation Hospital,Department of Urology
[3] Southern Medical University,Department of Urology, Zhujiang Hospital
[4] University of Iowa,Department of Urology
来源
Medical Oncology | 2014年 / 31卷
关键词
Prostate cancer; Percent Free prostate-specific antigen; Prostate-specific antigen; Biopsy;
D O I
暂无
中图分类号
学科分类号
摘要
The prostate-specific antigen (PSA) “gray zone” in Chinese men is likely higher than the traditional value (2.5–10.0 ng/ml) since the incidence of prostate cancer in Chinese men is relative low. The utility of percent free PSA in predicting prostate cancer is based on Western populations and may introduce sizable bias when applied to a Chinese cohort. We assessed the efficacy of percent free PSA in predicting prostate cancer in Chinese men with a PSA of 2.5–10.0 and 10.1–20.0 ng/ml. A total of 558 men with a PSA of 2.5–20.0 ng/ml who had undergone prostatic biopsy to detect prostate cancer from two Chinese centers were included. The rates of prostate cancer in different percent free PSA ranges were evaluated. Receiver operating characteristic curve (ROC) was used to evaluate and compare the efficiency of PSA and percent free PSA in the diagnosis of prostate cancer. The areas under ROC (AUCs) for percent free PSA for predicting prostate cancer were not higher than those for PSA, although prostate cancer detection rates increased with decreased percent free PSA in men with a PSA of 2.5–10.0, 10.1–20.0, and 2.5–20.0 ng/ml. Similarly, for men aged <70 and ≥70 years and with prostate volume <40 and ≥40 ml, AUCs showed percent free PSA was not better than PSA in predicting prostate cancer. By analyzing multicenter data, we first found that percent free PSA does not improve detection of prostate cancer in Chinese men with a PSA of 2.5–10.0 or 10.1–20.0 ng/ml.
引用
收藏
相关论文
共 95 条
  • [11] Albertsen PC(1997)Prostate cancer detection in men with serum PSA concentrations of 2.6–4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements JAMA 277 1452-337
  • [12] Babaian RJ(2002)The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml Eur Urol 42 333-109
  • [13] Carter HB(1997)The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia Cancer 79 104-592
  • [14] Gann PH(2010)Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data Jpn J Clin Oncol 40 588-180
  • [15] Han M(2012)Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: racial differences Prostate 72 173-748
  • [16] Catalona WJ(2013)Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0–10.0 and 10.1–20.0 ng/ml in Chinese men Urol Oncol 31 744-403
  • [17] Smith DS(2010)Impact of prostate volume on the diagnostic value of prostate cancer with different biopsy strategies Beijing Da Xue Xue Bao 42 400-1237
  • [18] Wolfert RL(1998)The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer J Urol 159 1234-864
  • [19] Wang TJ(2010)Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature Eur Urol 58 851-768
  • [20] Rittenhouse HG(2006)A meta-analysis of the performance characteristics of the free prostate-specific antigen test Urology 67 762-undefined